Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well giving bevacizumab together with erlotinib
hydrochloride works in treating patients with metastatic or unresectable biliary tumors.
Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some
block the ability of tumor cells to grow and spread. Others find tumor cells and help kill
them or carry tumor-killing substances to them. Erlotinib hydrochloride may stop the growth
of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab and
erlotinib hydrochloride may also stop the growth of tumor cells by blocking blood flow to the
tumor. Giving bevacizumab together with erlotinib hydrochloride may kill more tumor cells.